Although the precise mechanisms linking VTN to PD1/PD-L1 require further investigation, our data position VTN as both a prognostic biomarker for immunotherapy response and a therapeutic target to overcome resistance in pancreatic cancer. This evidence concerns the gene CD274 and familial pancreatic carcinoma.